Biotech · Private company
AnGes USA, Inc.
Track this companyFree. Adds AnGes USA, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials60 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- HGF Plasmid (AMG0001)Phase 3 · Critical Limb IschemiaClinicalTrials.gov · fetched Nov 12, 2026
- AMG0001Phase 2 · Peripheral Artery DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- HGF plasmidPhase 2 · Arterial Occlusive DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- HGF PlasmidPhase 2 · Critical Limb IschemiaClinicalTrials.gov · fetched Nov 12, 2026
- AMG0103Phase 1 · Degenerative Disc DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Subjects from Study AG-CLI-0206 who received AMG0001Critical Limb IschemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic UlcersPHASE2 · UNKNOWN · started Jan 30, 2020ClinicalTrials.gov NCT04267640 · fetched Nov 12, 2026
- AMG0103 in Subjects With Chronic Discogenic Lumbar Back PainPHASE1 · COMPLETED · started Feb 26, 2018ClinicalTrials.gov NCT03263611 · fetched Nov 12, 2026
- A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb IschemiaCOMPLETED · started Feb 20, 2017ClinicalTrials.gov NCT02974179 · fetched Nov 12, 2026
- Efficacy and Safety of AMG0001 in Subjects With Critical Limb IschemiaPHASE3 · TERMINATED · started Nov 12, 2014ClinicalTrials.gov NCT02144610 · fetched Nov 12, 2026
- A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb IschemiaPHASE2 · COMPLETED · started Nov 1, 2013ClinicalTrials.gov NCT02016755 · fetched Nov 12, 2026
- Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic UlcersPHASE2 · COMPLETED · started Aug 1, 2005ClinicalTrials.gov NCT00189540 · fetched Nov 12, 2026